Cytokine-induced killer (CIK) cells are a unique population of cytotoxic T lymphocytes (CTL) with the characteristic @entity5168 + @entity4497 + phenotype. These cells have demonstrated higher proliferative and cytolytic activities in comparison to the reported @entity5168 - @entity4497 + lymphokine activated killer (LAK) cells that are essentially activated natural killer (NK) cells. CIK cells are non-MHC-restricted in target cell recognition and killing. We have shown the feasibility of generating CIK cells from a series of marrow samples of @entity1 with @entity3052 ( @entity3052 ) collected at diagnosis. At maturity, the CIK cells exhibit potent @entity137 against @entity3052 as well as allogeneic @entity2800 cells, regardless of the HLA types of these targets. This observed @entity137 is not entirely due to NK cells as prior pre-absorption of the NK cells cytolytic activities does not abolish the subsequent cytotolytic activities against @entity1778 . It has also been reported by others that CIK cells are cytolytic against @entity1860 ( @entity1860 ) cells, both in vitro and in the @entity915 @entity19 @entity5 model. In a @entity19 transplant model across MHC barrier, the CIK cells generated from the donor do not induce graft vs. @entity2132 as observed for unfractionated donor splenocytes. In comparison to untreated control @entity19 , the infusion of CIK cells results in the prolonged survival of @entity19 @entity1778 -bearing @entity19 . CIK cells also express @entity68963 , part of the NK receptor comprising of @entity68963 -NKG2 heterodimer. However, only low level of the killer immunoglobulin-like receptors are expressed by the CIK cells. In addition, as reported for the classical CTL, CIK cells could interact with dendritic cells (DC) to result in the enhancement of cytotolytic activities against @entity5 cells. The characteristic biological properties of the CIK cells would, therefore, enable them to be exploited for anti-leukemic therapy.

Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity'] @entity19 :: ('10090', 'Species') :: ['mice', 'murine', 'mouse'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity5168 :: ('12501(Tax:10090)', 'Gene') :: ['CD3'] @entity2800 :: ('MESH:D007951', 'Disease') :: ['myeloid leukemia'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'autologous AML targets', 'AML'] @entity68963 :: ('16643(Tax:10090)', 'Gene') :: ['CD94'] @entity915 :: ('MESH:D053632', 'Disease') :: ['SCID'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemic targets', 'leukemia'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['host disease'] @entity1860 :: ('MESH:D015464', 'Disease') :: ['CML', 'chronic myeloid leukemia'] @entity4497 :: ('17967(Tax:10090)', 'Gene') :: ['CD56']
@entity1778 :: (MESH:D007938,Disease) :: ['leukemia']
